Nusinersen Therapy

Nusinersen Therapy is a pharmacotherapeutic intervention classified as an antisense oligonucleotide-based treatment that selectively modulates SMN2 gene splicing to increase production of functional survival motor neuron protein in patients with spinal muscular atrophy.

246

Publications

16.5K

Citations

1.8K

Authors

561

Institutions

Publications per year

2017–2026

243

Authors

1.8K

  1. TH
    Tim Hagenacker

    Essen University Hospital, Germany

    19 publications · 1.2K citations

    19

    h-index

  2. EM
    Eugenio Mercuri

    Università Cattolica del Sacro Cuore, Italy

    25 publications · 4.8K citations

    19

    h-index

  3. JK
    Janbernd Kirschner

    University Medical Center Freiburg, Germany

    23 publications · 5.8K citations

    19

    h-index

  4. DC
    Darryl C. De Vivo

    Columbia University, United States

    17 publications · 6.8K citations

    16

    h-index

  5. RS
    Richard S. Finkel

    Children's Hospital of Philadelphia, United States

    17 publications · 6.1K citations

    16

    h-index

1–5 of 1.8K

Venues

  1. Journal of Neuromuscular Diseases

    14 publications · 1K citations

    13

    h-index

  2. Muscle & Nerve

    13 publications · 642 citations

    13

    h-index

  3. Frontiers in Neurology

    10 publications · 259 citations

    11

    h-index

  4. Neurology

    10 publications · 1.2K citations

    11

    h-index

  5. Journal of Neurology

    10 publications · 608 citations

    11

    h-index

1–5